Successful treatment of epidermal growth factor receptor exon 19 deletion non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: A case report
No Thumbnail Available
Date
2024-12
Journal Title
Journal ISSN
Volume Title
Publisher
Wolters Kluwer – Medknow
Abstract
Osimertinib, a third‑generation epidermal growth factor receptor (EGFR)–tyrosine kinase inhibitor (TKI), has revolutionized one of the standard most efficient treatments for EGFR mutation‑positive non‑small cell lung cancer (NSCLC). Osimertinib, a third‑generation EGFR–TKI, is currently one of most efficient treatments in clinical practice. However, it has a potentially fatal side effect: interstitial lung disease (ILD). When severe ILD occurs, a drug substitution is often required, and there is a rising concern about which drug to choose to inhibit the progression of NSCLC and avoid aggravating while alleviating ILD. Herein, we report an NSCLC case with osimertinib‑induced ILD successfully rechallenged by almonertinib. In addition, we conducted a literature review on the clinical efficacy and adverse effects of almonertinib, hoping to provide insight into NSCLC treatment.
Description
Keywords
Almonertinib, interstitial lung disease, non‑small cell lung cancer, osimertinib
Citation
Li Zhichao, Wang Gang, Xue Guoliang, Wang Nan, Hu Yanting, Cao Pikun, Cai Hongchao, Wei Zhigang, Ye Xin . Successful treatment of epidermal growth factor receptor exon 19 deletion non-small cell lung cancer with almonertinib after osimertinib-induced interstitial lung disease: A case report. Journal of Cancer Research and Therapeutics. 2024 Dec; 20(7): 2148-2151